The IGF pathway is activated in insulinomas but downregulated in metastatic disease

Mieke E. R. Henfling, Aurel A. Perren, Anja M. Schmitt, Christiane M. Saddig, Achim A. Starke, Robert G. Riedl, Yvonne M. H. Versleijen-Jonkers, Diana M. Sprij-Mooij, Frans C. S. Ramaekers, Leo J. Hofland, Ernst-Jan M. Speel*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1005-1018
Number of pages14
JournalEndocrine-Related Cancer
Volume25
Issue number12
DOIs
Publication statusPublished - Dec 2018

Keywords

  • insulinoma
  • pancreatic neuroendocrine tumor (PanNET)
  • EGFR
  • IGF2
  • IGF1R
  • mTOR signaling
  • metastatic disease
  • GROWTH-FACTOR RECEPTOR
  • ENDOCRINE PANCREATIC TUMORS
  • NEUROENDOCRINE TUMORS
  • MTOR PATHWAY
  • FACTOR SYSTEM
  • EXPRESSION
  • SURVIVAL
  • ANTAGONISTS
  • EVEROLIMUS
  • PATTERNS

Cite this

Henfling, Mieke E. R. ; Perren, Aurel A. ; Schmitt, Anja M. ; Saddig, Christiane M. ; Starke, Achim A. ; Riedl, Robert G. ; Versleijen-Jonkers, Yvonne M. H. ; Sprij-Mooij, Diana M. ; Ramaekers, Frans C. S. ; Hofland, Leo J. ; Speel, Ernst-Jan M. / The IGF pathway is activated in insulinomas but downregulated in metastatic disease. In: Endocrine-Related Cancer. 2018 ; Vol. 25, No. 12. pp. 1005-1018.
@article{0f526ad36353458ba9a33e63809cc45f,
title = "The IGF pathway is activated in insulinomas but downregulated in metastatic disease",
keywords = "insulinoma, pancreatic neuroendocrine tumor (PanNET), EGFR, IGF2, IGF1R, mTOR signaling, metastatic disease, GROWTH-FACTOR RECEPTOR, ENDOCRINE PANCREATIC TUMORS, NEUROENDOCRINE TUMORS, MTOR PATHWAY, FACTOR SYSTEM, EXPRESSION, SURVIVAL, ANTAGONISTS, EVEROLIMUS, PATTERNS",
author = "Henfling, {Mieke E. R.} and Perren, {Aurel A.} and Schmitt, {Anja M.} and Saddig, {Christiane M.} and Starke, {Achim A.} and Riedl, {Robert G.} and Versleijen-Jonkers, {Yvonne M. H.} and Sprij-Mooij, {Diana M.} and Ramaekers, {Frans C. S.} and Hofland, {Leo J.} and Speel, {Ernst-Jan M.}",
year = "2018",
month = "12",
doi = "10.1530/ERC-18-0222",
language = "English",
volume = "25",
pages = "1005--1018",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "12",

}

Henfling, MER, Perren, AA, Schmitt, AM, Saddig, CM, Starke, AA, Riedl, RG, Versleijen-Jonkers, YMH, Sprij-Mooij, DM, Ramaekers, FCS, Hofland, LJ & Speel, E-JM 2018, 'The IGF pathway is activated in insulinomas but downregulated in metastatic disease', Endocrine-Related Cancer, vol. 25, no. 12, pp. 1005-1018. https://doi.org/10.1530/ERC-18-0222

The IGF pathway is activated in insulinomas but downregulated in metastatic disease. / Henfling, Mieke E. R.; Perren, Aurel A.; Schmitt, Anja M.; Saddig, Christiane M.; Starke, Achim A.; Riedl, Robert G.; Versleijen-Jonkers, Yvonne M. H.; Sprij-Mooij, Diana M.; Ramaekers, Frans C. S.; Hofland, Leo J.; Speel, Ernst-Jan M.

In: Endocrine-Related Cancer, Vol. 25, No. 12, 12.2018, p. 1005-1018.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The IGF pathway is activated in insulinomas but downregulated in metastatic disease

AU - Henfling, Mieke E. R.

AU - Perren, Aurel A.

AU - Schmitt, Anja M.

AU - Saddig, Christiane M.

AU - Starke, Achim A.

AU - Riedl, Robert G.

AU - Versleijen-Jonkers, Yvonne M. H.

AU - Sprij-Mooij, Diana M.

AU - Ramaekers, Frans C. S.

AU - Hofland, Leo J.

AU - Speel, Ernst-Jan M.

PY - 2018/12

Y1 - 2018/12

KW - insulinoma

KW - pancreatic neuroendocrine tumor (PanNET)

KW - EGFR

KW - IGF2

KW - IGF1R

KW - mTOR signaling

KW - metastatic disease

KW - GROWTH-FACTOR RECEPTOR

KW - ENDOCRINE PANCREATIC TUMORS

KW - NEUROENDOCRINE TUMORS

KW - MTOR PATHWAY

KW - FACTOR SYSTEM

KW - EXPRESSION

KW - SURVIVAL

KW - ANTAGONISTS

KW - EVEROLIMUS

KW - PATTERNS

U2 - 10.1530/ERC-18-0222

DO - 10.1530/ERC-18-0222

M3 - Article

VL - 25

SP - 1005

EP - 1018

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 12

ER -